An assessment of hormone replacement therapy to prevent postmenopausal osteoporosis

Osteoporosis International

Volumn 9, Issue SUPPL. 2, 1999, Pages

  Doren M ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ESTRADIOL; ESTROGEN; ESTRONE; GESTAGEN; TIBOLONE;

ADULT; AGED; BONE DENSITY; BONE MINERAL; CLIMACTERIUM; CLINICAL TRIAL; CONFERENCE PAPER; ESTROGEN THERAPY; FEMALE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

CASE-CONTROL STUDIES; COHORT STUDIES; ESTRADIOL; ESTRADIOL CONGENERS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); ESTRONE; FEMALE; HUMANS; MIDDLE AGED; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS;

EID: 0344673469     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004162     Document Type: Conference Paper

References (101)

1. Cooper C, Barrett-Connor E. Epidemiology of osteoporosis. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD, editors. Osteoporosis 1996. Proceedings of the 1996 World Congress on Osteoporosis. Amsterdam: Elsevier, 1996:75-7.
2. Anonymous. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva:WHO, 1994.
3. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
4. Seeman E. Growth in bone mass and size: are racial and gender differences in bone mineral density more apparent than real? [editorial] J Clin Endocrinol 1998;83:1414-9.
5. Lunt M, Felsenberg D, Adams J, et al. Population-based geographic variations in DXA bone density in Europe: the EVOS study. Osteoporos Int 1997;7:175-89.
6. Elffors I, Allander E, Kanis J, et al. The variable incidence of hip fracture in southern Europe: the MEDOS study. Osteoporos Int 1994;4:253-63.
7. Nilas L, Christiansen C. Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab 1987;65:697-702.
8. Nordin BEC, Need AG, Bridges A, Horowitz M. Relative contributions of years since menopause, age, and weight to vetebral density in postmenopausal women. J Clin Endocrinol Metab 1992;74:20-3.
9. Gambacciani M, Spinetti A, de Simone L et al. Postmenopausal bone loss of the proximal femur: estimated contributions of menopause and aging. Menopause 1995;2:169-74.
10. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study for osteoporotic fractures. J Clin Endocrinol Metab 1998;83:2239-43.
11. Khosla S, Atkinson EJ, Melton LJ III, Riggs BL. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. J Clin Endocrinol Metab 1997;82:1522-7.
12. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. Ann Intern Med 1996;125:360-8.
13. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-46.
14. Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F. A randomized study on the effects of estrogen-progestogen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 1989;10:313-20.
15. Glüer C-C for the International Quantitative Ultrasound Consensus Group. Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. J Bone Miner Res 1997;12:1280-8.
16. Garnero P, Delmas PD. Biochemical markers of bone turnover. Endocrinol Metab Clin North Am 1998;27:303-23.
17. Rosen CJ, Chesnut CH III, Mallinak NJS. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-10.
18. Anonymous. European consensus development conference on menopause. Hum Reprod 1996;83:693-700.
19. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5.
20. Henry D, Robertson J, O'Connell, Gillespie W. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1977 amd 1995. Climacteric 1998;1:92-111.
21. O'Connell D, Robertson J, Henry D, Gillespie W. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects. Climacteric 1998;1:112-23.
22. Lindsay R, Hart DM. Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759-62.
23. Harris ST, Genant HK, Baylink DJ, et al. The effects of estrone (Ogen) on spinal bone density of postmenopausal women. Arch Intern Med 1991;151:1980-4.
24. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy. Arch Intern Med 1997;157:2609-15.
25. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990;336:265-9.
26. Castelo-Branco C, Martinez de Osaba MJ, Pons F, Gonzalez-Merlo M. The effect of hormone replacement therapy on postmenopausal bone loss. Eur J Obstet Gynecol Reprod Biol 1992;44:131-6.
27. Castelo-Branco C, Pons F, Gonzalez-Merlo M. Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry. Maturitas 1993;16:133-7.
28. Lindsay R, Hart DM, Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. BMJ 1980;280:1207-9.
29. Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991;13:155-62.
30. Lyritis GP, Kaipathios S, Basdeskis K, et al. Prevention of postoophorectomy bone loss with Tibolone. Maturitas 1995;22:247-53.
31. Marslew U, Overgaard K, Riis BJ, Christiansen C. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992;79:202-10.
32. Marslew U, Riis BJ. Christiansen C. Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Eur J Clin Invest 1992;21:601-7.
33. Adami S, Suppi R, Bertoldo F, et al. Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner 1989;7:79-86.
34. Dören M, Reuther G, Minne HW, Schneider HPG. Superior compliance and efficacy of continuously combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 1995;73:1446-51.
35. Palacios S, Menéndez C, Jurado AR, Vargas JC. Effects of percutaneous oestradiol versus oral oestrogens on bone density. Maturitas 1995;20:209-13.
36. Christiansen C, Riis BJ. 17ß-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990;71:836-41.
37. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990;76:290-5.
38. Naéssen T, Persson I, Ljunghall S, Bergström S. Women with climacteric symptoms: a target group for prevention of rapid bone loss and osteoporosis. Osteoporos Int 1992;2:225-31.
39. Salamone L, Gregg E, Wolf RL, et al. Are menopausal symptoms associated with bone mineral density and changes in bone mineral density in premenopausal women? Maturitas 1998;29:179-87.
40. Munk-Jensen N, Overgaard K, Nilas L. Postmenopausal bone loss and response to hormone replacement therapy independent of climacteric symptoms. Menopause 1995;2:35-41.
41. Wimalawansa SJ, Kehely A, Banks LM, et al. The effects of percutaneous oestradiol and low dose human calcitonin in postmenopausal bone loss. In: Christiansen C, Johansen JS, Riis BJ, editors. Osteoporosis 1987. Copenhagen: Osteopress ApS, 1987;1:528-32.
42. Ribot C, Trémollières F, Pouilles JM, Louvet JP, Peyon R. Preventive effects of transdermal administration of 17β estradiol on postmenopausal bone loss: a 2-year prospective study. Gynecol Endocrinol 1989;3:259-68.
43. Reginster JY, Sarlet N, Deroisy R,. Albert A, Gaspard U, Franchimont P. Minimal levels of serum estradiol prevent postmenopausal bone loss. Calcif Tissue Int 1992;51:340-3.
44. Lindsay R, Hart DM, MacLean A, Clark AC, Kraszewski A, Garwood J. Bone response to termination of estrogen treatment. Lancet 1978;II:1325-7.
45. Christiansen C, Christensen MS, Transbøl I. Bone mass in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy. Lancet 1981;I:459-61.
46. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fracture Research Group. Ann Intern Med 1995;122:9-16.
47. Felson DT, Zhang Y, Hannan MT, Kiel DW, Wilson PWF, Andersen JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
48. Berman RS, Epstein RS, Lydick EG. Compliance of women taking estrogen replacement therapy. J Womens Health 1996;5:213-20.
49. de Souza MJ, Prestwood KM, Luciano AA, Miller BE, Nulsen JC. A comparison of the effect of synthetic and micronized hormone replacement therapy on bone mineral density and biochemical markers of bone metabolism. Menopause 1996;3:140-8.
50. Adachi JD, Sargeant EJ, Sagle MA, et al. A double-bind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy. Br J Obstet Gynaecol 1997;104:64-70.
51. Hirvonen E, Lamberg-Allardt C, Lankinen KS, Geurts P, Wilén-Rosenqvist G. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy. Br J Obstet Gynaecol 1997;104 (Suppl 16): 19-25.
52. Hirvonen E, Caccatiore B, Wahlström T, Rita H, Wilén-Rosenqvist G. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch. Br J Obstet Gynaecol 1997;104 (Suppl 16):26-31.
53. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996;276:1389-96.
54. Hosking D, Chilvers CED, Christiansen C et al for the Early Postmenopausal Intervention Cohort Study Group. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998;338:485-92.
55. Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1995;19:S191-3.
56. Speroff L, Rowan J, Symons J, Genant HK, Wilborn W for the CHART Study Group. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). JAMA 1996;276:1397-403.
57. Wimalawansa S. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995;99:36-42.
58. Anonymous. Consensus development conference. Prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107-10.
59. Lindsay RD, Hart DM, MacLean A, Garwood J, Clark AC, Kraszewski A. Bone loss during oestriol therapy in postmenopausal women. Maturitas 1979;1:279-85.
60. 3 in peri- and postmenopausal women: effects of bone loss and lipoprotein lipids. Chin Med J 1992;105:929-33.
61. Nozaki M, Hashimoto K, Inoue Y, Sano M, Nakano H. Usefulness of estriol for the treatment of bone loss in postmenopausal women. Nippon Sanka Fujinka Gakkai Zasshi 1996;48:83-8.
62. Devogelaer JP, Lecart C, Dupret P, de Nayer P, Nagant de Deuxchaisnes C. Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women. Maturitas 1998;28:243-9.
63. 3 and calcium lactate on vertebral bone loss in early menopausal women. Maturitas 1997;28:11-7.
64. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991;90:171-8.
65. Perrone G, Falaschi P, Capri O, et al. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. Int J Fertil 1994;39:202-7.
66. Abdalla H, Hart DM, Lindsay R, Leggate I, Hooke A. Prevention of bone loss in postmenopausal women by norethisterone. Obstet Gynecol 1985;66:789-92.
67. Klehr-Bathmann I, Kuhl H. Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Maturitas 1995;21:245-50.
68. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995; 85:529-37.
69. Birkenhäger JC, Erdtsieck RJ, Zeelenberg J, et al. Can nandrolone add to the effect of hormonal replacement therapy in postmenopausal osteoporosis ? Bone Miner 1992;18:251-65.
70. Garnett T, Studd J, Watson N, Savvas M, Leather A. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. Obstet Gynecol 1992;79:968-72.
71. Davis SR, McCloud P, Strauss BJG, Burger H. Testosterone enhances estradiols effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36.
72. Hassager C, Podenphant J, Riis B, et al. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. Metabolism 1989;38:238-42.
73. 3, or intermittent calcium infusions Maturitas 1986;8:281-9.
74. Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124-8.
75. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-74.
76. Nordin BEC. Calcium and osteoporosis. Nutrition 1997;13:664-72.
77. Reid IR. The roles of calcium and vitamin D in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998;27:389-98.
78. Dawson-Hughes B. Calcium, vitamin D and vitamin D metabolites. In: Wren BG, editor. Progress in the management of the menopause. Casterton Hall: Parthenon Publishing, 1997:299-303.
79. Cumming RG. Calcium intake and bone mass: a quantitative review of the evidence. Calcif Tissue Int 1990;47:194-201.
80. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-2.
81. Dawson-Hughes B, Harris SS, Krall A, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-6.
82. Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med 1996;124:400-6.
83. Riis BJ, Nilas L, Christiansen C. Does calcium potentiate the effect of estrogen therapy on postmenopausal bone loss? Bone Miner 1987;2:1-9.
84. Haines CJ, Chung TKH, Leung PC, Hsu SYC, Leung DHY. Calcium supplementation and bone mineral density in postmenopausal women using estrogen replacement therapy. Bone 1995;16:529-31.
85. Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998;67:18-24.
86. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987;106:40-5.
87. Davis JW, Ross PD, Johnson NE, et al. Estrogen and calcium supplement use among Japanese-American women: effects upon bone loss when used singly and in combination. Bone 1995;17:369-76.
88. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckmann M. Estrogen replacement therapy. I. A 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979;53:277-81.
89. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
90. Wimalawansa S. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998;104:219-26.
91. Windeler J, Lange S. Events per person year: a dubious concept. BMJ 1995;310:454-6.
92. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
93. Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995;5:23-9.
94. Michaëlsson K, Holmberg L, Mallmin H, Sörensen S, Wolk A, Bergström R. Diet and hip fracture risk: results from a case-control study. Int J Epidemiol 1995;24:771-82.
95. Naéssen T, Persson I, Adami H-O, Bergström R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. Ann Intern Med 1990;113:95-103.
96. Michaëlsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. BMJ 1998;16:1858-63.
97. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. JAMA 1997;277:543-7.
98. Naéssen T, Lindemark BM Larsen HC. Better postural balance in elderly women receiving estrogens. Am J Obstet Gynecol 1997;177:412-6.
99. Notelovitz M, Martin D, Tesar, R et al. Estrogen therapy and variable-resistance weight training increase bone mineral in surgically menopausal women. J Bone Miner Res 1991;6:583-90.
100. Kohrt WM, Ehsani AA, Birge SJ. HRT preserves increases in bone mineral density and reductions in body fat after a supervised exercise program. J Appl Physiol 1998;84:1506-12.
101. Heikkinen J, Kyllönen E, Kurttila-Matero E, et al. HRT and exercise: effects on bone density, muscle strength and lipid metabolism: a placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women. Maturitas 1997;26:139-49.